Skip to main content
. 2020 Nov 18;6(47):eabd1471. doi: 10.1126/sciadv.abd1471

Fig. 8. Pretreatment of PBMCs from patients with LN with Kv1.3-NPs before engraftment decreases CD40L and IFNγ production and increases survival in the humanized LN mice.

Fig. 8

(A) PBMCs from patients with LN were preincubated overnight with either scr-NPs or Kv1.3-NPs and engrafted in NSG mice. Ex vivo flow cytometry experiments were performed on these mice, and survival was recorded in a separate set of experiments. (B to D) Fluorescence intensities of CD40L (B), IFNγ (C), and Ki-67 (D) in splenocytes of LN mice pretreated with either scr-NPs or Kv1.3-NPs before engraftment, as shown in (A). Cells were stimulated with TG for 3 hours. Shown here are fluorescence intensities measured on days 2 and 7 after engraftment. Four to six mice were engrafted per group with PBMCs from two to three patients with LN. Each symbol represents an individual mouse. Horizontal red lines represent the means for each group. Significance was calculated by Student’s t test. (E) Survival in LN mice: PBMCs from patients with LN were treated with either scr-NPs or Kv1.3-NPs before engraftment. Kaplan-Meier survival curve is shown. Data are from 10 to 11 mice per group engrafted with PBMCs from two patients with LN. Significance was calculated by a log rank test.